{"id":10546,"date":"2026-07-11T11:08:01","date_gmt":"2026-07-11T05:38:01","guid":{"rendered":"https:\/\/www.rusanpharma.com\/blogs\/?p=10546"},"modified":"2026-08-01T15:50:02","modified_gmt":"2026-08-01T10:20:02","slug":"apomorphine-hydrochloride-hemihydrate-a-complete-guide-for-pharma-manufacturers","status":"publish","type":"post","link":"https:\/\/www.rusanpharma.com\/blogs\/apomorphine-hydrochloride-hemihydrate-a-complete-guide-for-pharma-manufacturers\/","title":{"rendered":"Apomorphine Hydrochloride Hemihydrate: A Complete Guide for Pharma Manufacturers"},"content":{"rendered":"\n

For pharmaceutical companies developing formulations for Parkinson’s disease management, sourcing a reliable Apomorphine Hydrochloride Hemihydrate API is one of the most critical decisions in the product development process. As a specialised manufacturer of complex neurological and de-addiction APIs, Rusan Pharma<\/strong> understands the technical and regulatory demands this molecule places on formulators, and this guide breaks down what manufacturers need to evaluate before finalising a supplier.<\/p>\n\n\n\n

Understanding the Molecule<\/strong><\/h2>\n\n\n\n

Apomorphine Hydrochloride Hemihydrate is a non-ergoline dopamine agonist derived synthetically from morphine, though it carries no opioid activity and is not classified as a narcotic. It acts primarily on D1 and D2 dopamine receptors in the brain, making it effective in managing acute “OFF” episodes in advanced Parkinson’s disease, where oral medications temporarily lose effectiveness. Because it undergoes extensive first-pass metabolism, it is formulated almost exclusively for parenteral, sublingual, or subcutaneous delivery rather than oral tablets.<\/p>\n\n\n\n

Key Manufacturing Considerations<\/strong><\/h2>\n\n\n\n

For formulators, working with this API requires close attention to several factors:<\/p>\n\n\n\n

    \n
  1. Photosensitivity and Oxidation Risk<\/strong> \u2013 Apomorphine is prone to oxidative degradation and colour change when exposed to light and air. Manufacturing environments must control light exposure, and packaging must use appropriate amber or opaque materials to preserve potency.<\/li>\n\n\n\n
  2. pH Sensitivity<\/strong> \u2013 Formulation stability is closely tied to pH control. Injectable and sublingual formulations require precise buffering to prevent degradation during shelf life.<\/li>\n\n\n\n
  3. Particle Size and Solubility<\/strong> \u2013 Since the compound is sparingly soluble in water, consistent particle size distribution from the API supplier directly affects dissolution rate and formulation uniformity, particularly for sublingual film or tablet development.<\/li>\n\n\n\n
  4. Sterility Requirements<\/strong> \u2013 For injectable formulations, the API must meet stringent bioburden and endotoxin specifications, requiring suppliers with validated aseptic processing capabilities or sterile-grade API production.<\/li>\n<\/ol>\n\n\n\n

    Regulatory Documentation Manufacturers Should Expect<\/strong><\/h2>\n\n\n\n

    A dependable API supplier should be able to provide comprehensive technical support, including:<\/p>\n\n\n\n